Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects

NCT01091831 is registered in ClinicalTrials.gov with Fondazione EMN Italy Onlus as lead sponsor.

NCT NCT01091831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01091831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects
Lead sponsor
Fondazione EMN Italy Onlus
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2009
Completion date
July 1, 2024
Enrollment
389 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma